Niehr, F., Weichert, W., Stenzinger, A., Budach, V., & Tinhofer, I. (2015). CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab. J Transl Med.

Niehr, Franziska, Wilko Weichert, Albrecht Stenzinger, Volker Budach, und Ingeborg Tinhofer. "CCI-779 (Temsirolimus) Exhibits Increased Anti-tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells With Acquired Resistance to Cisplatin or Cetuximab." J Transl Med 2015.

Niehr, Franziska, et al. "CCI-779 (Temsirolimus) Exhibits Increased Anti-tumor Activity in Low EGFR Expressing HNSCC Cell Lines and Is Effective in Cells With Acquired Resistance to Cisplatin or Cetuximab." J Transl Med 2015.